Skip to main content

Table 3 Switching and discontinuation patterns among triptan users

From: The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review

Citation

Country

Triptans (forms)

n

PS (%)

Time point for DCS, WCS, and BCS

DC (%)

WCS (%)

BCS (% of total cohort)

Overall

Opioid

NSAIDsab

BAR

Ergots

Chen, 2014 [36]

Taiwan

suma, riza (oral, sc)

13,951

4.0 by 2-yrs

1st refill

24.8

0.01

40.9

1.2

18.8

0

11.3

Fischer, 2016 [37]

Austria

ele, frova, suma, zolmi (NR)

126

NR

1st follow-up visit

10.8

15.1

14.6a

NAa

14.6ab

NR

NR

Katic, 2011 [38]

US

almo, nara, ele, frova, suma, riza, zolmi (all)

40,892

6.4 by 2-yrs

1st refill

13.7

4.0

36.2

18.2

12.5

2.6

0

Lombard, 2018 [39]c

US

NR

124,556

15.0 by 1-yr

with one change after 1-year

22.5

3.2

29.1

15.5

11.6a

1.9

NR

Ng-Mak, 2012 [40]

UK

almo, ele, frova, nara, riza, suma, zolmi (oral)

3618

13.0 by 2-yr

1st refill

48.5

4.9

2.3

0.1

0.9

0

0.2

France

2051

6.0 by 2-yr

1st refill

54.9

6.8

4.0

0

2

0

0.6

Germany

954

9.0 by 2-yr

1st refill

54.7

6.3

2.3

0

1.3

0

0.1

  1. Abbreviations: BAR Barbiturates, BCS Between class switches, DC Discontinuers, EU Europe, NR Not reported, PS Persistent users, SC Subcutaneous inj, US United States, WCS Within class switches, yr(s) Year(s)
  2. aAcute medication other than triptans included nonsteroidal anti-inflammatory drugs and paracetamol. Opioids are not used in clinical routine for treatment of migraine headache in Austria
  3. bNSAIDs/acetaminophen
  4. cIn Lombard et al. there were 30% of patients who had 2+ switched, and not further information was given to characterize switching among these patients